Vitamin C Improves Dasatinib Concentrations Under Hypochlorhydric Conditions of the Simulated Stomach Duodenum Model

Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of ga...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical research Vol. 39; no. 9; pp. 2217 - 2226
Main Authors Moghrabi, Fouad S., Aburub, Aktham, Fadda, Hala M.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.09.2022
Springer
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0724-8741
1573-904X
1573-904X
DOI10.1007/s11095-022-03321-y

Cover

Abstract Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions. Methods A dynamic, in vitro , multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGF hypo ) and FaSGF hypo with 1000 mg of vitamin C. Results Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC ∞ was observed in FaSGF hypo . Upon addition of vitamin C to FaSGF hypo , drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC ∞ in the duodenal compartment were similar in both FaSGF and FaSGF hypo . The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs. Conclusions The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients.
AbstractList PurposepH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions.MethodsA dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGFhypo) and FaSGFhypo with 1000 mg of vitamin C.ResultsSignificant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC∞ was observed in FaSGFhypo. Upon addition of vitamin C to FaSGFhypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC∞ in the duodenal compartment were similar in both FaSGF and FaSGFhypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs.ConclusionsThe SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients.
pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions.PURPOSEpH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions.A dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGFhypo) and FaSGFhypo with 1000 mg of vitamin C.METHODSA dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGFhypo) and FaSGFhypo with 1000 mg of vitamin C.Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC∞ was observed in FaSGFhypo. Upon addition of vitamin C to FaSGFhypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC∞ in the duodenal compartment were similar in both FaSGF and FaSGFhypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs.RESULTSSignificant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC∞ was observed in FaSGFhypo. Upon addition of vitamin C to FaSGFhypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC∞ in the duodenal compartment were similar in both FaSGF and FaSGFhypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs.The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients.CONCLUSIONSThe SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients.
pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions. A dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGF.sub.hypo) and FaSGF.sub.hypo with 1000 mg of vitamin C. Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC.sub.[infinity] was observed in FaSGF.sub.hypo. Upon addition of vitamin C to FaSGF.sub.hypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC.sub.[infinity] in the duodenal compartment were similar in both FaSGF and FaSGF.sub.hypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs. The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients.
Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions. Methods A dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGF.sub.hypo) and FaSGF.sub.hypo with 1000 mg of vitamin C. Results Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC.sub.[infinity] was observed in FaSGF.sub.hypo. Upon addition of vitamin C to FaSGF.sub.hypo, drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC.sub.[infinity] in the duodenal compartment were similar in both FaSGF and FaSGF.sub.hypo. The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs. Conclusions The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients.
Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs). The objective of this study is to investigate the influence of gastric pH on dasatinib supersaturation and determine if vitamin C (L-ascorbic acid) can improve dasatinib concentrations under simulated hypochlorhydric gastric conditions. Methods A dynamic, in vitro , multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time curves. Dasatinib and lamotrigine were explored under normal, fasted, simulated gastric fluids (pH 2) (FaSGF), hypochlorhydric simulated gastric fluids (pH 4.5) (FaSGF hypo ) and FaSGF hypo with 1000 mg of vitamin C. Results Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC ∞ was observed in FaSGF hypo . Upon addition of vitamin C to FaSGF hypo , drug concentrations were restored to those observed in FaSGF. Lamotrigine AUC ∞ in the duodenal compartment were similar in both FaSGF and FaSGF hypo . The in vitro trends observed for dasatinib and lamotrigine are reflective of the trends observed in vivo in subjects receiving treatment with ARAs. Conclusions The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides a promising approach for improving bioavailability of poorly soluble, weakly basic drugs in hypochlorhydric patients.
Audience Academic
Author Aburub, Aktham
Moghrabi, Fouad S.
Fadda, Hala M.
Author_xml – sequence: 1
  givenname: Fouad S.
  surname: Moghrabi
  fullname: Moghrabi, Fouad S.
  organization: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Butler University
– sequence: 2
  givenname: Aktham
  surname: Aburub
  fullname: Aburub, Aktham
  organization: Synthetic Molecule Design and Development, Lilly Research Labs, Eli Lilly & Company
– sequence: 3
  givenname: Hala M.
  surname: Fadda
  fullname: Fadda, Hala M.
  email: hfadda@butler.edu
  organization: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Butler University
BookMark eNp9kU1rFTEUhoNU8Lb6B1wF3LiZevIxNzPLcqu2UHFRK-5Ckkl6U2aSa5IR5t-b6wjFIiWLQ8LzHHLOe4pOQgwWobcEzgmA-JAJgb5tgNIGGKOkWV6gDWkFa3rgP07QBgTlTSc4eYVOc34AgI70fIPKd1_U5APe4evpkOIvm_Glyqr44DXexWBsKKleY8j4Lgw24avlEM1-jGm_DMmbIzT4FYgOl73Ft36aR1XsgG9LnJTZ48s5DjbME_5S6_gavXRqzPbN33qG7j59_La7am6-fr7eXdw0hpO2NJ3SQjurXNtqMJSZXgzEDcS0htJWM22c1gqMFkMd3hLacwWUMNe3xIEBdober33rYD9nm4ucfDZ2HFWwcc6SbjsOvQDOK_ruCfoQ5xTq7yQVlAou2LZ7pO7VaKUPLtbdmGNTeSEo2Ypupc7_Q9Uz2MmbGpzz9f0foVsFk2LOyTppairHlVbRj5KAPKYs15RlTVn-SVkuVaVP1EPyk0rL8xJbpVzhcG_T47DPWL8BS7u9TQ
CitedBy_id crossref_primary_10_1016_j_ijpharm_2022_122069
crossref_primary_10_1021_jacs_3c12502
crossref_primary_10_1016_j_dmpk_2023_100502
Cites_doi 10.1007/s002280000146
10.1208/s12248-016-9918-x
10.1200/JCO.2015.65.2560
10.1007/s12247-009-9071-5
10.1021/acs.molpharmaceut.5b00154
10.1016/j.xphs.2018.11.005
10.2165/11592630-000000000-00000
10.1093/ajcn/78.5.999
10.1007/BF02088565
10.1016/j.xphs.2018.07.023
10.1021/mp500196f
10.1016/j.ccell.2018.07.014
10.1002/cpt.1569
10.1007/s002280050438
10.1128/AAC.39.8.1671
10.1177/0091270009333854
10.1021/mp400403s
10.1038/clpt.2012.73
10.1016/j.ijpharm.2022.121722
10.1038/clpt.2014.87
10.1177/1533210110392951
10.1080/07315724.2003.10719272
10.1177/1078155217692152
10.1023/a:1018918316253
10.1155/2010/957842
10.1021/acs.molpharmaceut.1c00690
10.1016/j.ijpharm.2011.04.018
10.1208/s12248-014-9673-9
10.1248/bpb.24.313
10.1177/1758835918818347
10.1073/pnas.93.8.3704
10.1007/s00228-008-0576-5
10.1002/cncr.31917
10.3390/nu13020615
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022
COPYRIGHT 2022 Springer
The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.
2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022
– notice: COPYRIGHT 2022 Springer
– notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.
– notice: 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
DBID AAYXX
CITATION
3V.
7RV
7TK
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s11095-022-03321-y
DatabaseName CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni)
PML(ProQuest Medical Library)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)
MEDLINE - Academic



Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1573-904X
EndPage 2226
ExternalDocumentID A721678368
10_1007_s11095_022_03321_y
GrantInformation_xml – fundername: Fulbright Association
  funderid: http://dx.doi.org/10.13039/100010629
– fundername: Butler University
  funderid: http://dx.doi.org/10.13039/100006354
GroupedDBID ---
-4W
-56
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
123
199
1N0
1SB
2.D
203
28-
29O
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3SX
3V.
4.4
406
408
409
40D
40E
53G
5QI
5VS
67N
67Z
6NX
78A
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYOK
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYPR
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFDYV
AFEXP
AFGCZ
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
EPAXT
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
IHE
IHR
IJ-
IKXTQ
IMOTQ
INH
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
L7B
LAK
LLZTM
LSO
M1P
M4Y
MA-
MK0
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SBY
SCLPG
SDH
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TEORI
TSG
TSK
TSV
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WH7
WJK
WK6
WK8
WOW
YCJ
YLTOR
Z45
Z5O
Z7S
Z7U
Z7V
Z7W
Z7X
Z81
Z82
Z83
Z84
Z87
Z88
Z8N
Z8O
Z8P
Z8Q
Z8R
Z8V
Z8W
Z91
Z92
ZGI
ZMTXR
ZOVNA
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PUEGO
7TK
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c415t-8ab7bfeaf55b0c23c97d1fd1c5c225b3bcfbba0cb7d095e1294a0213f951f0c03
IEDL.DBID AGYKE
ISSN 0724-8741
1573-904X
IngestDate Thu Sep 04 17:37:41 EDT 2025
Mon Oct 06 17:23:47 EDT 2025
Mon Oct 20 22:18:56 EDT 2025
Mon Oct 20 16:37:46 EDT 2025
Wed Oct 01 04:30:29 EDT 2025
Thu Apr 24 23:07:29 EDT 2025
Fri Feb 21 02:45:31 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords Proton pump inhibitors
Oral drug delivery
Ionization
Dissolution
correlations
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c415t-8ab7bfeaf55b0c23c97d1fd1c5c225b3bcfbba0cb7d095e1294a0213f951f0c03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PQID 2722747368
PQPubID 37334
PageCount 10
ParticipantIDs proquest_miscellaneous_2684097044
proquest_journals_2722747368
gale_infotracmisc_A721678368
gale_infotracacademiconefile_A721678368
crossref_citationtrail_10_1007_s11095_022_03321_y
crossref_primary_10_1007_s11095_022_03321_y
springer_journals_10_1007_s11095_022_03321_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-01
PublicationDateYYYYMMDD 2022-09-01
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
PublicationSubtitle An Official Journal of the American Association of Pharmaceutical Scientists
PublicationTitle Pharmaceutical research
PublicationTitleAbbrev Pharm Res
PublicationYear 2022
Publisher Springer US
Springer
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer
– name: Springer Nature B.V
References Zhang, Wu, Lee, Zhao, Zhang (CR2) 2014; 96
Borjian, Ferrari, Anouf, Touyz (CR37) 2010; 2010
van Leeuwen, Peric, Hussaarts, Kienhuis, NS IJ, de Bruijn P (CR32) 2016; 34
Kirchheiner, Glatt, Fuhr, Klotz, Meineke, Seufferlein (CR4) 2009; 65
Sharma, Holmes, Mehta, Chen, Aparasu, Shih (CR40) 2019; 125
CR18
Vaidhyanathan, Wang, Crison, Varia, Gao, Saxena (CR19) 2019; 108
CR38
Morihara, Aoyagi, Kaniwa, Kojima, Ogata (CR10) 2001; 24
Ebert, Thong, Oertel, Kirch (CR17) 2000; 56
Bhattachar, Risley, Werawatganone, Aburub (CR21) 2011; 412
Jaruratanasirikul, Sriwiriyajan (CR8) 1998; 54
Fletcher, Breeze, Shetty (CR29) 2003; 78
Shenoy, Creagan, Witzig, Levine (CR30) 2018; 34
CR31
van Seyen, Colbers, Abbink, Drenth, Burger (CR35) 2019; 106
Budha, Frymoyer, Smelick, Jin, Yago, Dresser (CR1) 2012; 92
Guo, Sun (CR12) 2022; 619
Fish, Young, Shah, Gao (CR22) 2009; 4
Lake-Bakaar, Elsakr, Hagag, Lyubsky, Ahuja, Craddock (CR11) 1996; 41
Knoebel, Larson (CR36) 2018; 24
Levine, Conry-Cantilena, Wang, Welch, Washko, Dhariwal (CR25) 1996; 93
Schlueter, Johnston (CR28) 2011; 16
CR3
Honigford, Aburub, Fadda (CR14) 2019; 108
CR6
Hussaarts, Veerman, Jansman, van Gelder, Mathijssen, van Leeuwen (CR7) 2019; 11
Guo, Sun (CR41) 2022; 19
Smelick, Heffron, Chu, Dean, West, Duvall (CR39) 2013; 10
Nader, Quinney, Fadda, Foster (CR15) 2016; 18
Mitra, Fadda (CR16) 2014; 11
CR27
Vaithianathan, Raman, Jiang, Ting, Kane, Polli (CR20) 2015; 12
CR26
Yago, Frymoyer, Benet, Smelick, Frassetto, Ding (CR23) 2014; 16
CR24
Walravens, Brouwers, Spriet, Tack, Annaert, Augustijns (CR34) 2011; 50
Russell, Berardi, Barnett, O'Sullivan, Wagner, Dressman (CR9) 1994; 11
Padayatty, Katz, Wang, Eck, Kwon, Lee (CR13) 2003; 22
Eley, Luo, Agrawal, Sanil, Manning, Li (CR5) 2009; 49
Chin, Loeb, Fong (CR33) 1995; 39
3321_CR31
L Zhang (3321_CR2) 2014; 96
T Eley (3321_CR5) 2009; 49
S Vaithianathan (3321_CR20) 2015; 12
MR Yago (3321_CR23) 2014; 16
GS Smelick (3321_CR39) 2013; 10
Y Guo (3321_CR41) 2022; 19
K Hussaarts (3321_CR7) 2019; 11
AE Fletcher (3321_CR29) 2003; 78
RW van Leeuwen (3321_CR32) 2016; 34
U Ebert (3321_CR17) 2000; 56
A Borjian (3321_CR37) 2010; 2010
NR Budha (3321_CR1) 2012; 92
N Shenoy (3321_CR30) 2018; 34
M Morihara (3321_CR10) 2001; 24
Y Guo (3321_CR12) 2022; 619
A Mitra (3321_CR16) 2014; 11
AM Nader (3321_CR15) 2016; 18
3321_CR38
3321_CR18
RW Knoebel (3321_CR36) 2018; 24
WP Fish (3321_CR22) 2009; 4
J Walravens (3321_CR34) 2011; 50
SJ Padayatty (3321_CR13) 2003; 22
G Lake-Bakaar (3321_CR11) 1996; 41
AK Schlueter (3321_CR28) 2011; 16
TL Russell (3321_CR9) 1994; 11
SN Bhattachar (3321_CR21) 2011; 412
TW Chin (3321_CR33) 1995; 39
3321_CR6
3321_CR3
M Sharma (3321_CR40) 2019; 125
CR Honigford (3321_CR14) 2019; 108
S Vaidhyanathan (3321_CR19) 2019; 108
S Jaruratanasirikul (3321_CR8) 1998; 54
3321_CR27
M Levine (3321_CR25) 1996; 93
J Kirchheiner (3321_CR4) 2009; 65
3321_CR24
3321_CR26
M van Seyen (3321_CR35) 2019; 106
References_xml – volume: 56
  start-page: 299
  issue: 4
  year: 2000
  end-page: 304
  ident: CR17
  article-title: Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280000146
– ident: CR18
– volume: 18
  start-page: 981
  issue: 4
  year: 2016
  end-page: 988
  ident: CR15
  article-title: Effect of Gastric Fluid Volume on the Dissolution and Absorption of BCS Class II Drugs: a Case Study with Nifedipine
  publication-title: AAPS J
  doi: 10.1208/s12248-016-9918-x
– volume: 34
  start-page: 1309
  issue: 12
  year: 2016
  end-page: 14
  ident: CR32
  article-title: Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2015.65.2560
– volume: 4
  start-page: 165
  year: 2009
  end-page: 173
  ident: CR22
  article-title: The Use of Experimental Design Principles in Dissolution Method Development: Development of a Discriminating Dissolution Method for Sprycel Film-Coated Tablets
  publication-title: J Pharm Innov
  doi: 10.1007/s12247-009-9071-5
– volume: 12
  start-page: 2436
  issue: 7
  year: 2015
  end-page: 2443
  ident: CR20
  article-title: Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.5b00154
– volume: 108
  start-page: 741
  issue: 1
  year: 2019
  end-page: 749
  ident: CR19
  article-title: Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2018.11.005
– volume: 50
  start-page: 725
  issue: 11
  year: 2011
  end-page: 734
  ident: CR34
  article-title: Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations
  publication-title: Clin Pharmacokinet
  doi: 10.2165/11592630-000000000-00000
– volume: 78
  start-page: 999
  issue: 5
  year: 2003
  end-page: 1010
  ident: CR29
  article-title: Antioxidant vitamins and mortality in older persons: findings from the nutrition add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/78.5.999
– volume: 41
  start-page: 1398
  issue: 7
  year: 1996
  end-page: 1408
  ident: CR11
  article-title: Changes in parietal cell structure and function in HIV disease
  publication-title: Dig Dis Sci
  doi: 10.1007/BF02088565
– volume: 108
  start-page: 288
  issue: 1
  year: 2019
  end-page: 294
  ident: CR14
  article-title: A Simulated Stomach Duodenum Model Predicting the Effect of Fluid Volume and Prandial Gastric Flow Patterns on Nifedipine Pharmacokinetics From Cosolvent-Based Capsules
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2018.07.023
– volume: 11
  start-page: 2835
  issue: 8
  year: 2014
  end-page: 2844
  ident: CR16
  article-title: Effect of surfactants, gastric emptying, and dosage form on supersaturation of dipyridamole in an model simulating the stomach and duodenum
  publication-title: Mol Pharm
  doi: 10.1021/mp500196f
– volume: 34
  start-page: 700
  issue: 5
  year: 2018
  end-page: 706
  ident: CR30
  article-title: Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.07.014
– volume: 106
  start-page: 1093
  issue: 5
  year: 2019
  end-page: 1098
  ident: CR35
  article-title: Concomitant Intake of Coca-Cola to Manage the Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.1569
– ident: CR6
– volume: 54
  start-page: 159
  issue: 2
  year: 1998
  end-page: 161
  ident: CR8
  article-title: Effect of omeprazole on the pharmacokinetics of itraconazole
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050438
– ident: CR27
– volume: 39
  start-page: 1671
  issue: 8
  year: 1995
  end-page: 1675
  ident: CR33
  article-title: Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.39.8.1671
– volume: 49
  start-page: 700
  issue: 6
  year: 2009
  end-page: 709
  ident: CR5
  article-title: Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270009333854
– volume: 10
  start-page: 4055
  issue: 11
  year: 2013
  end-page: 4062
  ident: CR39
  article-title: Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development
  publication-title: Mol Pharm
  doi: 10.1021/mp400403s
– volume: 92
  start-page: 203
  issue: 2
  year: 2012
  end-page: 213
  ident: CR1
  article-title: Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2012.73
– volume: 619
  year: 2022
  ident: CR12
  article-title: Profound effects of gastric secretion rate variations on the precipitation of erlotinib in duodenum - An investigation
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2022.121722
– volume: 96
  start-page: 266
  issue: 2
  year: 2014
  end-page: 277
  ident: CR2
  article-title: pH-Dependent Drug-Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2014.87
– volume: 16
  start-page: 49
  issue: 1
  year: 2011
  end-page: 57
  ident: CR28
  article-title: Vitamin C: Overview and update
  publication-title: Journal of Evidence-Based Complementary and Alternative Medicine
  doi: 10.1177/1533210110392951
– volume: 22
  start-page: 18
  issue: 1
  year: 2003
  end-page: 35
  ident: CR13
  article-title: Vitamin C as an antioxidant: evaluation of its role in disease prevention
  publication-title: J Am Coll Nutr
  doi: 10.1080/07315724.2003.10719272
– ident: CR3
– volume: 24
  start-page: 156
  issue: 2
  year: 2018
  end-page: 158
  ident: CR36
  article-title: Pepsi(R) or Coke(R)? Influence of acid on dasatinib absorption
  publication-title: J Oncol Pharm Pract
  doi: 10.1177/1078155217692152
– ident: CR38
– volume: 11
  start-page: 136
  issue: 1
  year: 1994
  end-page: 143
  ident: CR9
  article-title: pH-related changes in the absorption of dipyridamole in the elderly
  publication-title: Pharm Res
  doi: 10.1023/a:1018918316253
– ident: CR31
– volume: 2010
  year: 2010
  ident: CR37
  article-title: Pop-cola acids and tooth erosion: an , , electron-microscopic, and clinical report
  publication-title: Int J Dent
  doi: 10.1155/2010/957842
– volume: 19
  start-page: 432
  issue: 2
  year: 2022
  end-page: 439
  ident: CR41
  article-title: Pharmaceutical Lauryl Sulfate Salts: Prevalence, Formation Rules, and Formulation Implications
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.1c00690
– volume: 412
  start-page: 95
  issue: 1–2
  year: 2011
  end-page: 98
  ident: CR21
  article-title: Weak bases and formation of a less soluble lauryl sulfate salt/complex in sodium lauryl sulfate (SLS) containing media
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2011.04.018
– volume: 16
  start-page: 1358
  issue: 6
  year: 2014
  end-page: 1365
  ident: CR23
  article-title: The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria
  publication-title: AAPS J
  doi: 10.1208/s12248-014-9673-9
– volume: 24
  start-page: 313
  issue: 3
  year: 2001
  end-page: 315
  ident: CR10
  article-title: Assessment of gastric acidity of Japanese subjects over the last 15 years
  publication-title: Biol Pharm Bull
  doi: 10.1248/bpb.24.313
– volume: 11
  start-page: 1758835918818347
  year: 2019
  ident: CR7
  article-title: Clinically relevant drug interactions with multikinase inhibitors: a review
  publication-title: Ther Adv Med Oncol
  doi: 10.1177/1758835918818347
– ident: CR26
– ident: CR24
– volume: 93
  start-page: 3704
  issue: 8
  year: 1996
  end-page: 3709
  ident: CR25
  article-title: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.93.8.3704
– volume: 65
  start-page: 19
  issue: 1
  year: 2009
  end-page: 31
  ident: CR4
  article-title: Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-008-0576-5
– volume: 125
  start-page: 1155
  issue: 7
  year: 2019
  end-page: 1162
  ident: CR40
  article-title: The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer
  publication-title: Cancer
  doi: 10.1002/cncr.31917
– ident: 3321_CR26
– volume: 18
  start-page: 981
  issue: 4
  year: 2016
  ident: 3321_CR15
  publication-title: AAPS J
  doi: 10.1208/s12248-016-9918-x
– volume: 56
  start-page: 299
  issue: 4
  year: 2000
  ident: 3321_CR17
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280000146
– volume: 54
  start-page: 159
  issue: 2
  year: 1998
  ident: 3321_CR8
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050438
– volume: 16
  start-page: 49
  issue: 1
  year: 2011
  ident: 3321_CR28
  publication-title: Journal of Evidence-Based Complementary and Alternative Medicine
  doi: 10.1177/1533210110392951
– ident: 3321_CR24
– volume: 96
  start-page: 266
  issue: 2
  year: 2014
  ident: 3321_CR2
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2014.87
– volume: 108
  start-page: 741
  issue: 1
  year: 2019
  ident: 3321_CR19
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2018.11.005
– volume: 92
  start-page: 203
  issue: 2
  year: 2012
  ident: 3321_CR1
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2012.73
– ident: 3321_CR18
– volume: 4
  start-page: 165
  year: 2009
  ident: 3321_CR22
  publication-title: J Pharm Innov
  doi: 10.1007/s12247-009-9071-5
– volume: 10
  start-page: 4055
  issue: 11
  year: 2013
  ident: 3321_CR39
  publication-title: Mol Pharm
  doi: 10.1021/mp400403s
– volume: 11
  start-page: 2835
  issue: 8
  year: 2014
  ident: 3321_CR16
  publication-title: Mol Pharm
  doi: 10.1021/mp500196f
– volume: 49
  start-page: 700
  issue: 6
  year: 2009
  ident: 3321_CR5
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270009333854
– volume: 2010
  year: 2010
  ident: 3321_CR37
  publication-title: Int J Dent
  doi: 10.1155/2010/957842
– ident: 3321_CR38
– volume: 125
  start-page: 1155
  issue: 7
  year: 2019
  ident: 3321_CR40
  publication-title: Cancer
  doi: 10.1002/cncr.31917
– ident: 3321_CR6
– volume: 619
  year: 2022
  ident: 3321_CR12
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2022.121722
– volume: 93
  start-page: 3704
  issue: 8
  year: 1996
  ident: 3321_CR25
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.93.8.3704
– volume: 65
  start-page: 19
  issue: 1
  year: 2009
  ident: 3321_CR4
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-008-0576-5
– volume: 34
  start-page: 700
  issue: 5
  year: 2018
  ident: 3321_CR30
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.07.014
– volume: 16
  start-page: 1358
  issue: 6
  year: 2014
  ident: 3321_CR23
  publication-title: AAPS J
  doi: 10.1208/s12248-014-9673-9
– volume: 34
  start-page: 1309
  issue: 12
  year: 2016
  ident: 3321_CR32
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2015.65.2560
– ident: 3321_CR27
– volume: 106
  start-page: 1093
  issue: 5
  year: 2019
  ident: 3321_CR35
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.1569
– volume: 108
  start-page: 288
  issue: 1
  year: 2019
  ident: 3321_CR14
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2018.07.023
– volume: 11
  start-page: 136
  issue: 1
  year: 1994
  ident: 3321_CR9
  publication-title: Pharm Res
  doi: 10.1023/a:1018918316253
– volume: 50
  start-page: 725
  issue: 11
  year: 2011
  ident: 3321_CR34
  publication-title: Clin Pharmacokinet
  doi: 10.2165/11592630-000000000-00000
– volume: 24
  start-page: 156
  issue: 2
  year: 2018
  ident: 3321_CR36
  publication-title: J Oncol Pharm Pract
  doi: 10.1177/1078155217692152
– volume: 11
  start-page: 175883591881834
  year: 2019
  ident: 3321_CR7
  publication-title: Ther Adv Med Oncol
  doi: 10.1177/1758835918818347
– volume: 41
  start-page: 1398
  issue: 7
  year: 1996
  ident: 3321_CR11
  publication-title: Dig Dis Sci
  doi: 10.1007/BF02088565
– volume: 12
  start-page: 2436
  issue: 7
  year: 2015
  ident: 3321_CR20
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.5b00154
– volume: 19
  start-page: 432
  issue: 2
  year: 2022
  ident: 3321_CR41
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.1c00690
– volume: 412
  start-page: 95
  issue: 1–2
  year: 2011
  ident: 3321_CR21
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2011.04.018
– volume: 78
  start-page: 999
  issue: 5
  year: 2003
  ident: 3321_CR29
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/78.5.999
– ident: 3321_CR31
  doi: 10.3390/nu13020615
– ident: 3321_CR3
– volume: 24
  start-page: 313
  issue: 3
  year: 2001
  ident: 3321_CR10
  publication-title: Biol Pharm Bull
  doi: 10.1248/bpb.24.313
– volume: 39
  start-page: 1671
  issue: 8
  year: 1995
  ident: 3321_CR33
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.39.8.1671
– volume: 22
  start-page: 18
  issue: 1
  year: 2003
  ident: 3321_CR13
  publication-title: J Am Coll Nutr
  doi: 10.1080/07315724.2003.10719272
SSID ssj0008194
Score 2.4138446
Snippet Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase...
Purpose pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase...
pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor...
PurposepH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase...
SourceID proquest
gale
crossref
springer
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 2217
SubjectTerms Ascorbic acid
Bioavailability
Biochemistry
Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Biomedicine
Dasatinib
Drugs
Duodenum
Enzyme inhibitors
Football (College)
Lamotrigine
Medical Law
Original Research Article
Patients
pH effects
Pharmacology/Toxicology
Pharmacy
Protein-tyrosine kinase
Reducing agents
Small intestine
Trends
Tyrosine
Vitamin C
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LaxsxEBapc-mlpC-6bVpUKOmhFpW02tehlNRJMIUa0yQlt0WPXWxIdp14fdh_n5l9eHFDctYTzWg0kub7hpAvSgcuDkPH8LeRKadClsTOssQFoQ4jLmyO75B_ZuH0Uv2-Cq72yKzHwmBYZW8TG0PtSotv5N9lJPEC5Yfxz9Utw6xR-Lvap9DQXWoF96OhGHtG9iUyY43I_q_T2fzv1jbD-dcQSkVSgR1QooPRtGA6wRu0smTc96Vg9c5R9b_BfvBz2hxIZwfkRedJ0uNW9C_JXla8Ikfzloq6HtOLAVm1HtMjOh9IquvXpPq3rPTNsqAT2r4rZGt6ojG0p1gaOkEwY9Ex6q5pkxyJTutVaRdwv1_UDqwnVnJtwBctcwqOJD1f3mA2sMzR86qEsRb0ZFM6DLanmHPt-g25PDu9mExZl4GBWTjYKxZrE5k803kQGG6lb5PIidwJG1iwA8Y3NjdGc2siB2uXge-gNDgNfg5-W84t99-SUVEW2TtCeWQ1uAtSci2U0cI47WKeOATmxi4QHhH9Yqe2oyfHLBnX6UCsjAJKQUBpI6C09si3bZtVS87xZO2vKMMUdy70bHUHQID5IQdWeow8RghqiT1yuFMTdpzdLe61IO12_Dod9NMjn7fF2BKj2Iqs3EAdZNZJIq6UR8a99gxdPD7190-P-IE8l43eYujbIRlVd5vsI_hKlfnUbYB7XJUQzg
  priority: 102
  providerName: ProQuest
Title Vitamin C Improves Dasatinib Concentrations Under Hypochlorhydric Conditions of the Simulated Stomach Duodenum Model
URI https://link.springer.com/article/10.1007/s11095-022-03321-y
https://www.proquest.com/docview/2722747368
https://www.proquest.com/docview/2684097044
Volume 39
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVLSH
  databaseName: SpringerLink Journals
  customDbUrl:
  mediaType: online
  eissn: 1573-904X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0008194
  issn: 0724-8741
  databaseCode: AFBBN
  dateStart: 19970101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1573-904X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0008194
  issn: 0724-8741
  databaseCode: AGYKE
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1573-904X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0008194
  issn: 0724-8741
  databaseCode: U2A
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9swDBbW9LLL1r2wbF2gAUN3WFzI8kP2MUmTBRsWBGszZCdDDxsJltpF7RzcXz_SjwTpHkBPPoiSZZmkCInfR0I-uNIzge8bC28bLde4vhUGRluh8XzpC2brBM8hv8386cL9svSWDSgsb7Pd2yvJylPvwW42q9DE3GKOw22rPCLHFd9WhxwPPv_8Ot55YNjlKtoowV2wdtduwDJ_H-VgQ7rvlv-4H622nclTsmgnXGeb_DrfFupc393jcnzoF52QJ00cSge14jwjj-L0OTmb10TWZZ9e7XFZeZ-e0fme4rp8QYof60Jer1M6ovWpRJzTC4mJQela0RFCIdOGjzenVWklOi1vMr3aZLer0oDvRSFTp4vRLKEQhtLL9TXWEosNvSwyeNeKXmwzg6n6FCu2bV6SxWR8NZpaTf0GS0NYUFiBVEIlsUw8TzHNHR0KYyfG1p4GL6IcpROlJNNKGFiHGCIPV0LI4SQQ9SVMM-cV6aRZGr8mlAktIdjgnEnbVdJWRpqAhQZhvYHx7C6x258Y6YbcHGtsbKI9LTMudgSLHVWLHZVd8mnX56am9viv9EfUjQjtHkbWsoEvwPyQQSsaIAsSQmKCLjk9kAR71YfNrXZFjb_IIy44Hg9Uze93zdgTc-DSONuCDPLyhIK5bpf0W4XaD_Hvqb95mPhb8phXOomJdKekU9xu43cQeRWqR47EUvTA3CbD4azXmB08h-PZ_Du0LvjgN3T3Kbk
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9gAXxFMYCiwSlAOxul6vX4cKlaRVStsooinqzezDViKldqgdIf85fhszfiQKiN569r7kmZ2Z3Z3vG0LeC-mZ0PeNja-NtjDCt6PQaDsyni_9gDk6xXvI85E_vBRfr7yrLfK7w8JgWmVnE2tDbXKNd-T7POB4gHL98PPip41Vo_B1tSuhIdvSCuagphhrgR2nSfULjnDFwckA5P2B8-OjSX9ot1UGbA3Oq7RDqQKVJjL1PMU0d3UUGCc1jvY06LpylU6VkkyrwEA4koB_FBIco5tCbJIyzVwY9x7ZEa6I4PC38-VoNP628gXgb2sCq4ALsDvCaWE7DXjPYTU6mtvMdbljVxuu8W8H8c9Lbe0Ajx-Rh23kSg8bVXtMtpLsCdkbN9TXVY9O1kiuokf36HhNil09JeX3WSmvZxnt0-YeIynoQGIqUTZTtI_gyaxl8C1oXYyJDqtFrqfz_GZaGbDW2Mg0CWY0TykErvRido3VxxJDL8oc5prSwTI3mNxPscbb_Bm5vBNZPCfbWZ4lLwhlgZYQnnDOpCOUdJSRJmSRQSBwaDzHIk73s2Pd0qFjVY55vCZyRgHFIKC4FlBcWeTTqs-iIQO5tfVHlGGMlgJG1rIFPMD6kHMrPkTeJATRhBbZ3WgJO1xvfu60IG4tTBGv94NF3q0-Y0_MmsuSfAltkMknCpgQFul12rMe4v9Lf3n7jG_J_eHk_Cw-OxmdviIPeK3DmHa3S7bLm2XyGuK0Ur1pNwMlP-56__0B1GNPeg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkBAviKsIG2AkGA80muNcnDwgNLVUHYOp0jbUt8yXRK3UJd2SCuWv8es4J5dGBbG3Pcexo5yr7fN9h5D3nvRNGATGxttG2zNeYEeh0XZk_EAGgjk6xXPIH6fB5ML7NvNnO-R3h4XBssrOJ9aO2uQaz8gPueC4gXKD8DBtyyKmo_GX1bWNHaTwprVrp9GoyElS_YLtW_H5eASy_sD5-Ov5cGK3HQZsDYGrtEOphEoTmfq-Ypq7OhLGSY2jfQ16rlylU6Uk00oYSEUSiI2ehKDoppCXpEwzF-a9R-4L142wnFDMNps9jLQ1dZXgHngcz2kBOw1sz2E1LprbzHW5Y1dbQfHv0PDPHW0d-saPyaM2Z6VHjZI9ITtJ9pQcTBvS62pAz3sMVzGgB3Ta02FXz0j5c1HKq0VGh7Q5wUgKOpJYRJQtFB0ibDJruXsLWrdhopNqlev5Mr-ZVwb8NA4yTWkZzVMKKSs9W1xh37HE0LMyh7XmdLTODZb1U-zutnxOLu5EEi_IbpZnyUtCmdASEhPOmXQ8JR1lpAlZZBACHBrfsYjT_exYt0To2I9jGfcUziigGAQU1wKKK4t82ryzamhAbh39EWUYo4-AmbVsoQ7wfci2FR8hYxLCZ0KL7G-NBNvW2487LYhb31LEvSVY5N3mMb6J9XJZkq9hDHL4RIJ5nkUGnfb0U_z_01_dvuJb8gCsLv5-fHqyRx7yWoWx3m6f7JY36-Q1JGilelNbAiWXd216fwClyE0U
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vitamin+C+Improves+Dasatinib+Concentrations+Under+Hypochlorhydric+Conditions+of+the+Simulated+Stomach+Duodenum+Model&rft.jtitle=Pharmaceutical+research&rft.au=Moghrabi%2C+Fouad+S.&rft.au=Aburub%2C+Aktham&rft.au=Fadda%2C+Hala+M.&rft.date=2022-09-01&rft.pub=Springer+US&rft.issn=0724-8741&rft.eissn=1573-904X&rft.volume=39&rft.issue=9&rft.spage=2217&rft.epage=2226&rft_id=info:doi/10.1007%2Fs11095-022-03321-y&rft.externalDocID=10_1007_s11095_022_03321_y
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0724-8741&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0724-8741&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0724-8741&client=summon